Clinical Trial Search

Primary: Efficacy: Complete Clearance of Baseline External Genital and Perianal Warts at or Before Week 12 — 2; 5; 2; 10 Participants

Primary: Proportion of Subjects Achieving Complete Clearance of All Warts (Baseline and New) at the End of Study. — 0.248; 0.294; 0.09 proportion of participants

Primary: Proportion of Subjects With Complete Clearance of All Warts (Both Presented at Baseline and Newly Emerged Warts) at End of Study — 0.191; 0.272; 0.103 participants

Primary: HPV DNA and HIV Status — 96; 19; 4; 5 participants

Primary: Change in Wart Number — 0.5 warts

Primary: Change in the Maximum Size of the Genital Wart Lesion Over the Trial Period (as Measured in mm) — 8; 6; 11; 7 Participants

Primary: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts at the Study Day 84 (End of Treatment) Visit. — 11; 1; 9; 0 Participants — p=0.0048

Primary: Number of Participants With Complete Clearance, — 0; 0; 3; 5 participants

Primary: Percentage of Verrucae Cleared — 67.6 percentage of verrucae clearance

Primary: Proportion of Subjects With Treatment Emergent AEs After Application of A-101 45% for the Treatment of Common Warts — 70; 116 Participants

Primary: The Primary Efficacy Endpoint is the Number of Subjects Whose Identified Common Warts Are Determined to be Clear on the PWA Scale (PWA=0) at Visit 10 (Day 60) — 40; 13…

Primary: Clinical Clearance of Warts — 13; 4; 2 # of warts

Primary: Complete Clearance of Disease at Week 14 — 1; 0; 0; 0 participants — p=0.862

Primary: Change in Total Oral Mucosal Area Covered by Warts. — 11; 2 participants — p=0.30

Primary: The Primary Efficacy Endpoint is the Number of Subjects Whose Identified Common Warts Are Determined to be Clear on the PWA Scale (PWA=0) at Visit 10 (Day 60) — 33; 8…

Primary: Human Papillomavirus (HPV) Types in External Genital Warts (EGW) — 80; 12.66; 0.66; 2 percentage of participants

Primary: Number of Participants With Clinical Resolution of Injected Wart — 9; 1; 1 Participants

Primary: Incidence of HPV 6/11/16/18-related Cervical Intraepithelial Neoplasia (CIN)(Any Grade), Adenocarcinoma In Situ (AIS) or Cervical Cancer — 0; 1.2 incidence rate per 100…

Primary: Base Study: Incidence of Human Papillomavirus (HPV) Type 6/11/16/18-related External Genital Warts, Penile/Perianal/Perineal Intraepithelial Neoplasia (PIN), Penile…

Primary: Number and Percentage of Subjects With Total Disappearance of All Warts Within All Treated Areas. — 100; 102; 12 Participants

Primary: Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at the EOS Visit (Day 84) — 4 Participants

Primary: Number of Subjects With Complete Resolution of a Primary Injected Wart(s) at Any Treatment or Follow-up Visit — 16; 29; 31; 29 Participants — p=0.0329

Primary: Percentage of Participants With Time to First GH Recurrence — 43; 71 Percentage of participants — p=<0.001

Primary: Number of Participants With Complete Resolution of Primary Injected Wart — 19 Participants

Primary: Mean Change in Physician's Wart Assessment Score From Baseline to Day 57 — -0.77; -0.23 score on a scale (PWA)

Primary: Proportion of Patients With Regression of Perianal High-grade Squamous Intraepithelial Lesions (HSIL) — 0.515 proportion of participants

Primary: Physician's Wart Assessment — 1.52; 2.23 score on a scale

Primary: Efficacy Based on Mean Change in Physician Wart Assessment Over Time — -0.38; -1.00; -0.44 units on a scale — p=0.555

Primary: Percentage of Participants Achieving Complete Response in 5-FU Arm and Observation Arm Using ITT Population — 5; 9 Participants — p=0.1877

Primary: Diameter of the Wart — -0.12 cm